Table 3.
Changes in Total, Impact, Activity, and Symptom Scores in the SGRQ between Visits 1 and 4
| Visit 1 (71 Placebo/69 Cipro) | Visit 4 (64 Placebo/63 Cipro) | Visit 4 − Visit 1 (63 Placebo/61 Cipro) | P Value (Visit 4 − Visit 1, by Treatment) | |
|---|---|---|---|---|
| SGRQ total, placebo | 52.4 (17.2) | 47.8 (16.0) | −3.37 (11.5) | |
| SGRQ total, cipro | 53.4 (18.1) | 50.5 (17.8) | −1.93 (9.1) | 0.440 |
| SGRQ impact, placebo | 40.8 (20.0) | 38.5 (18.4) | −1.97 (12.8) | |
| SGRQ impact, cipro | 39.0 (20.0) | 35.8 (17.8) | −0.74 (10.8) | 0.560 |
| SGRQ activity, placebo | 68.2 (21.8) | 65.1 (20.2) | −1.74 (17.1) | |
| SGRQ activity, cipro | 67.3 (21.7) | 67.8 (22.5) | 1.17 (12.8) | 0.283 |
| SGRQ symptoms, placebo | 66.4 (15.3) | 54.3 (19.3) | −11.3 (20.1) | |
| SGRQ symptoms, cipro | 68.9 (16.6) | 55.7 (22.0) | −11.5 (21.5) | 0.949 |
Definition of abbreviations: cipro = ciprofloxacin; SGRQ = St. George’s Respiratory Questionnaire.
Data are shown as mean (SD).